Robin Park

1.4k total citations
68 papers, 904 citations indexed

About

Robin Park is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Robin Park has authored 68 papers receiving a total of 904 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 16 papers in Surgery. Recurrent topics in Robin Park's work include Cancer Immunotherapy and Biomarkers (21 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Gastric Cancer Management and Outcomes (10 papers). Robin Park is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Pancreatic and Hepatic Oncology Research (10 papers) and Gastric Cancer Management and Outcomes (10 papers). Robin Park collaborates with scholars based in United States, South Korea and Brazil. Robin Park's co-authors include Anwaar Saeed, Weijing Sun, Anup Kasi, Jong Dae Ji, Breanna Ford, Leslie A. Bateman, Daniel K. Nomura, Stephen K. Williamson, Won Jin Lee and Allen S. Lichter and has published in prestigious journals such as Nucleic Acids Research, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Robin Park

63 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robin Park United States 18 435 268 166 154 149 68 904
Omeed Moaven United States 22 421 1.0× 448 1.7× 164 1.0× 457 3.0× 130 0.9× 62 1.2k
Alexandra Pohl United States 15 539 1.2× 332 1.2× 243 1.5× 208 1.4× 196 1.3× 20 1.1k
Xiaohan Ren China 22 211 0.5× 408 1.5× 370 2.2× 100 0.6× 266 1.8× 52 972
Haijun Zhong China 13 353 0.8× 318 1.2× 279 1.7× 334 2.2× 167 1.1× 59 1.1k
Zhifang Jia China 19 312 0.7× 329 1.2× 232 1.4× 207 1.3× 179 1.2× 57 953
Xianwei Mo China 17 269 0.6× 293 1.1× 211 1.3× 183 1.2× 214 1.4× 62 788
Tianyi Gao China 20 268 0.6× 777 2.9× 143 0.9× 111 0.7× 598 4.0× 47 1.3k
Jason Yongsheng Chan Singapore 19 403 0.9× 500 1.9× 213 1.3× 129 0.8× 184 1.2× 107 1.2k
Sylvain Kirzin France 18 699 1.6× 218 0.8× 244 1.5× 560 3.6× 79 0.5× 41 1.2k

Countries citing papers authored by Robin Park

Since Specialization
Citations

This map shows the geographic impact of Robin Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robin Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robin Park more than expected).

Fields of papers citing papers by Robin Park

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robin Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robin Park. The network helps show where Robin Park may publish in the future.

Co-authorship network of co-authors of Robin Park

This figure shows the co-authorship network connecting the top 25 collaborators of Robin Park. A scholar is included among the top collaborators of Robin Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robin Park. Robin Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saeed, Anwaar, Paul E. Oberstein, Dan G. Duda, et al.. (2025). S2303: phase II/III trial of paclitaxel + ramucirumab ± nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE). Future Oncology. 21(11). 1325–1331.
2.
Park, Robin & Christine H. Chung. (2024). Advanced Human Papillomavirus–Negative Head and Neck Squamous Cell Carcinoma: Unmet Need and Emerging Therapies. Molecular Cancer Therapeutics. 23(12). 1717–1730. 1 indexed citations
3.
Park, Robin, et al.. (2024). Phase Ib trial of IRX-2 plus durvalumab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma. Oral Oncology. 154. 106866–106866. 3 indexed citations
4.
Saeed, Anwaar, Robin Park, Junqiang Dai, et al.. (2023). Cabozantinib plus durvalumab in advanced gastroesophageal cancer and other gastrointestinal malignancies: Phase Ib CAMILLA trial results. Cell Reports Medicine. 4(2). 100916–100916. 23 indexed citations
5.
Jeon, Justin Y., Tae Hoon Lee, Edward Kim, et al.. (2023). 581P The effect of exercise intervention on defecation related symptoms of colorectal cancer patients a randomized controlled trial. Annals of Oncology. 34. S424–S425.
6.
Park, Robin, et al.. (2023). Promising Novel Biomarkers for Hepatocellular Carcinoma: Diagnostic and Prognostic Insights. Journal of Hepatocellular Carcinoma. Volume 10. 1105–1127. 8 indexed citations
7.
8.
Park, Robin, Manik Amin, & Nikolaos A. Trikalinos. (2022). Temozolomide duration and secondary hematological neoplasms: A literature review and implications for patients with neuroendocrine neoplasms. Journal of Neuroendocrinology. 34(7). e13178–e13178. 3 indexed citations
9.
Park, Robin, et al.. (2021). Exceptional response to Erlotinib monotherapy in EGFR Exon 19-deleted, KRAS wild-type, Chemo-refractory advanced pancreatic adenocarcinoma. Cancer Treatment and Research Communications. 27. 100342–100342. 4 indexed citations
10.
11.
Park, Robin, et al.. (2021). B7–H3 regulates osteoclast differentiation via type I interferon-dependent IDO induction. Cell Death and Disease. 12(11). 971–971. 11 indexed citations
12.
Modi, Deepak, et al.. (2020). Cutaneous Paraneoplastic Syndrome Associated with Anal Squamous Cell Carcinoma: A Rare Presentation of an Uncommon Cancer. Current Oncology. 27(4). 433–435. 3 indexed citations
13.
14.
Saeed, Anwaar, Hannah Hildebrand, Robin Park, et al.. (2020). Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): A Retrospective Study. Journal of Clinical Medicine. 9(9). 2682–2682. 4 indexed citations
15.
Park, Robin, et al.. (2020). Immuno-Oncotherapeutic Approaches in Advanced Hepatocellular Carcinoma. Vaccines. 8(3). 447–447. 25 indexed citations
16.
17.
Park, Robin, Alisdair R. Philp, Alykhan S. Nagji, & Anup Kasi. (2020). Pathologically Complete Response after Triple Therapy in Locally Advanced Esophageal Cancer in a Hereditary Hemorrhagic Telangiectasia Patient. Case Reports in Oncology. 13(1). 176–181.
18.
Park, Robin, Stephen K. Williamson, Anup Kasi, & Anwaar Saeed. (2018). Immune Therapeutics in the Treatment of Advanced Gastric and Esophageal Cancer. Anticancer Research. 38(10). 5569–5580. 35 indexed citations
19.
Park, Robin, Tae‐Hwan Kim, & Jong Dae Ji. (2016). Gene Expression Profile in Patients with Axial Spondyloarthritis: Meta-analysis of Publicly Accessible Microarray Datasets. Journal of Rheumatic Diseases. 23(6). 363–363. 8 indexed citations
20.
Park, Robin, Arthur A. Bergen, Salman T. Qureshi, et al.. (2015). Cyclosporine A Treatment Inhibits Abcc6-Dependent Cardiac Necrosis and Calcification following Coxsackievirus B3 Infection in Mice. PLoS ONE. 10(9). e0138222–e0138222. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Omeed Moaven Breakdown of academic impact, for papers by Alexandra Pohl Breakdown of academic impact, for papers by Xiaohan Ren Breakdown of academic impact, for papers by Haijun Zhong Breakdown of academic impact, for papers by Zhifang Jia Breakdown of academic impact, for papers by Xianwei Mo Breakdown of academic impact, for papers by Tianyi Gao Breakdown of academic impact, for papers by Jason Yongsheng Chan Breakdown of academic impact, for papers by Sylvain Kirzin
Rankless by CCL
2026